Company: PHR
Filing Date: 2025-05-28
Form Type: 10-Q
Source: 0001412408-25-000039
Chunk: 146

Company: Phreesia, Inc.
Filing Date: 2025-05-28
Form: 10-Q
Item: Part I, Item 8
Chunk 146
---
 notes thereto included in our Annual Report on Form 10-K for the fiscal year ended January 31, 2025, filed with the SEC on March 13, 2025. Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report on Form 10-Q, including information with respect to our plans and strategy for our business, includes forward-looking statements based upon current plans, expectations and beliefs that involve risks and uncertainties. As a result of many factors, including those factors set forth under “Risk Factors” and “Special Note Regarding Forward-Looking Statements: in this Quarterly Report on Form 10-Q, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the follow discussion and analysis.

Financial Highlights

•Total revenue increased 15% to $115.9 million in the three months ended April 30, 2025, as compared to $101.2 million in the three months ended April 30, 2024.

•Net loss was $3.9 million in the three months ended April 30, 2025, as compared to $19.7 million in the three months ended April 30, 2024.

•Adjusted EBITDA was $20.8 million in the three months ended April 30, 2025, as compared to $4.1 million in the three months ended April 30, 2024.

•Net cash provided by operating activities was $14.9 million for the three months ended April 30, 2025, as compared to net cash used in operating activities of $0.7 million for the three months ended April 30, 2024.

•Free cash flow was $7.5 million for the three months ended April 30, 2025, as compared to negative $6.2 million for the three months ended April 30, 2024.

•Cash and cash equivalents as of April 30, 2025 was $90.9 million, an increase of $6.7 million as compared to January 31, 2025.

For a reconciliation of Adjusted EBITDA to net loss and a reconciliation of free cash flow to net cash provided by (used in) operating activities, and for more information as to how we calculate such measures, see the section below titled “Non-GAAP financial measures.”

Overview

We are a leading provider of comprehensive software solutions that improve the operational and financial performance of healthcare organizations and